SIRT6 and cardiac hypertrophy: At the pharmaceutical level, epigallocatechin-3-gallate (EGCG) blocked NF-κB DNA-binding activity to protect against cardiac hypertrophy mediated through the PSMB5-Nmnat2-SIRT6 axis [185, 186].